Global and United States EGFR Mutation Test Market Report & Forecast 2022-2028

Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are referred to as EGFR-mutated tumors. EGFR mutation is generally observed in NSCLCs, especially in adenocarcinoma tumors. According to the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society, there are around 50% of surgically resected lung adenocarcinomas in EGFR mutations. These mutations are related to micro papillary predominant subtype and the bronchioloalveolar carcinoma. EGFR biomarker is used in diagnosis of patients with NSCLC. Targeted therapy involving tyrosine kinase inhibitors such as gefitinib and erotinib is used in the treatment of patients with NSCLC. EGFR biomarker detects the presence of specific alterations in EGFR gene, which may lead to the development of tumor.
Market Analysis and Insights: Global and United States EGFR Mutation Test Market
This report focuses on global and United States EGFR Mutation Test market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global EGFR Mutation Test market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, DNA Sequencing accounting for % of the EGFR Mutation Test global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Cancer Hospitals was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
Increasing global prevalence of lung cancer is expected to fuel growth of the global EGFR mutation test market over the forecast period. Increasing adoption of biomarker therapy is also expected to boost growth of the market worldwide over the forecast period.
Global EGFR Mutation Test Scope and Market Size
EGFR Mutation Test market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global EGFR Mutation Test market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the EGFR Mutation Test market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
DNA Sequencing
Kits

Segment by Application
Cancer Hospitals
Clinical Research Institutes

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Abbott
Merck
Thermo Fisher Scientific
Illumina
BioMerieux
QIAGEN
Agilent Technologies
Hologic
Novartis
Roche
Genomic Health